Abstract 372P
Background
Stage III NSCLC, a heterogeneous disease with poor prognosis despite multimodal treatment, warrants study of treatment patterns. The patterns and survival outcomes in real-world pre-immuno-oncology (IO) era in Singapore were studied.
Methods
Retrospective data were collected from 3 centers (part of the KINDLE observational study) on patients diagnosed with stage III NSCLC between 01JAN2013 and 31DEC2017, with at least 9 months (m) of available records. Descriptive and inferential statistics were used to analyze clinico-demographics, treatment patterns, and their correlation with progression free survival (PFS) and overall survival (OS).
Results
Characteristics for 210 patients: median age 63 years (range 36-86), 72.4% men, 65.7% ever smoked, 61.8% with stage IIIA NSCLC (AJCC 7th ed.), and 90.9% with ECOG score of 0/1. Histology types were adenocarcinoma (61.4%) and squamous cell carcinoma (24.8%); 43.3 % had EGFR mutations. Of the 17 first-line regimens, predominant were concurrent chemoradiotherapy (cCRT, 31.2%), radiotherapy (12.9%), and sequential CRT (sCRT, 6.9%). Median PFS was 11.5m, 95% confidence interval (CI) 9.33-13.86 (14.3m [IIIA] vs 6.5m [IIIB], hazards ratio [HR] 0.553, p=0.0002); median OS was 26.3m, 95%CI 22.80-37.09 (40.7m [IIIA] vs 17.1m [IIIB], HR 0.515, p=0.0002). cCRT (HR 0.621, p=0.003) and surgery (HR 0.485, p=0.002) were associated with longer PFS and OS, respectively. In stage IIIA, surgery+CT (p=0.03) and cCRT (p=0.004) were associated with longer OS than CT alone; cCRT was associated with better OS than EGFR-TKI (p =0.044) in all stage IIIA and in unresectable stage IIIA and IIIB with EGFR mutations. In stage IIIB, cCRT (p<0.0001), sCRT (p=0.015), and EGFR-TKI (p=0.040) were associated with longer OS than RT alone; cCRT was associated with longer OS than CT alone (p=0.0014). With cCRT, median OS for unresectable stage IIIA and IIIB was 50.8m in EGFR+ and 25m in EGFR-.
Conclusions
Similar to the main KINDLE study, this subset reveals varied treatment practices for stage III NSCLC. Poor OS with existing treatment patterns reiterates the unmet medical need of the pre-IO era. This calls for improved access to newer medicines and quality care.
Clinical trial identification
D133HR00004.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
A. Kumar, R. Huggenberger, S. Robb: Full/Part-time employment: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session